Under-reporting of conflicts of interest among trialists: a cross-sectional study

Journal of the Royal Society of Medicine

Volumn 108, Issue 3, 2015, Pages 101-107

  Rasmussen, Kristine ^a,b   Schroll, Jeppe ^b   Gøtzsche, Peter C ^b   Lundh, Andreas ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Rigshospitalet   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

clinical trials; conflicts of interest; disclosure; drug industry

Indexed keywords

ARTICLE; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SCREENING; PHYSICIAN; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; PUBLICATION; CLINICAL TRIAL (TOPIC); DENMARK; INTERPERSONAL COMMUNICATION; PERSONNEL; PREVALENCE; STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDIES; DENMARK; DISCLOSURE; PREVALENCE; RESEARCH PERSONNEL;

EID: 84925233403     PISSN: 01410768     EISSN: 17581095     Source Type: Journal    
DOI: 10.1177/0141076814557878     Document Type: Article

References (20)

1. Evans I,Thornton H,Chalmers I,Glasziou PTesting Treatments. Better Research for Better Healthcare. 2nd edn. London: Pinter & Martin Ltd, 2011.London: Pinter & Martin Ltd; 2011:
2. Chan A,Altman DG.Epidemiology and reporting of randomised trials published in PubMed journals.Lancet. 2005;365:1159-1162
3. Lundh A,Sismondo S,Lexchin J,Busuioc OA,Bero L.Industry sponsorship and research outcome.Cochrane Database Syst Rev. 2012;12:MR000033-MR000033
4. Wang AT,McCoy CP,Murad MH,Montori VM.Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.BMJ. 2010;340:c1344-c1344
5. Stelfox HT,Chua G,O’Rourke K,Detsky AS.Conflict of interest in the debate over calcium-channel antagonists.N Engl J Med. 1998;338:101-106
6. Lerner TG,Miranda MDC,Lera AT,Ueda A,Briones B,Del Giglio A, et al.The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials.Contemp Clin Trials. 2012;33:1019-1022
7. Conflict of Interest in Medical Research, Education, and Practice. Lo BField MJ, ed. Washington, DC: Institute of Medicine of the National Academies; 2009:
8. ICMJE Form for Disclosure of Potential Conflicts of Interests. See: http://www.icmje.org/conflicts-of- interest (last checked 21 September 2014).
9. Neuman J,Korenstein D,Ross JS,Keyhani S.Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study.BMJ. 2011;343:1-8
10. The Danish Medicines Agency. List of Permissions Granted to Physicians and Dentists Affiliated with Pharmaceutical Companies.
11. Godlee F.A sunshine act for Europe.BMJ. 2011;343:d6593-d6593
12. Carpenter D,Joffe S.A unique researcher identifier for the Physician Payments Sunshine Act.JAMA. 2011;305:2007-2008
13. National Board of Health. Danish Authorisation Register. See: http://www.sst.dk/DS/OpslagAutReg.aspx (last checked 21 September 2014).
14. Jensen HG, Ministeriet for Sundhed og Forebyggelse. Vejl læger og tandlæger – apotekerlovens § 3, stk. 2. 2009:1–8. See: https://sundhedsstyrelsen.dk/da/ medicin/tilknytning-til-virksomhed/spoergsmaal-og-svar (last checked 21 September 2014).
15. Transparency International. Transparency International Corruption Perceptions Index 2012. See: http://transparency.org/cpi2012/results (last checked 21 September 2014).
16. Norris SL,Holmer HK,Ogden LA,Burda BU,Fu R.Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study.BMC Med Ethics. 2012;13:24-24
17. Chimonas S,Frosch Z,Rothman DJ.From disclosure to transparency: the use of company payment data.Arch Intern Med. 2011;171:81-86
18. McCartney M,Goldacre B,Chalmers I,Reynolds C,Mendel J,Smith S, et al.Why the GMC should set up a central registry of doctors’ competing interests.BMJ. 2014;348:1-2
19. Dyer C.Who is paying your doctor?.BMJ. 2014;4601:2013-2015
20. Wilson M.Is transparency really a panacea?.J R Soc Med. 2014;107:216-217